Therabron Therapeutics Inc

Therabron Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company based in Rockville, Maryland. With a team of 20 to 49 employees, the company is focused on developing novel therapeutic proteins to address a range of respiratory conditions. Therabron specializes in a new class of drugs based on the naturally occurring secretoglobin family of proteins. Their lead product candidate is a proprietary preparation of recombinant human CC10 protein (rhCC10), which has shown potential in treating various respiratory diseases. The company's technology platform allows for the creation, development, and commercialization of this unique class of proteins. Therabron's mission is to improve long-term health outcomes for patients suffering from neglected and under-treated respiratory conditions. They are targeting a range of diseases impacting individuals from infancy through adulthood, including bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute sinusitis, asthma, and pulmonary fibrosis. Therabron believes their innovative approach has the potential to significantly reduce healthcare costs associated with these prevalent illnesses. Interested parties can learn more about Therabron Therapeutics by visiting their website at therabron.com.